Cite
HARVARD Citation
Iles, K. et al. (2022). Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?. American surgeon. 88 (3), pp. 471-479. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Iles, K. et al. (2022). Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?. American surgeon. 88 (3), pp. 471-479. [Online].